Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA
- PMID: 18251696
- DOI: 10.1586/14760584.7.1.83
Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA
Abstract
In the year 2000, a heptavalent pneumococcal conjugate vaccine (PCV7) was licensed and recommended for routine immunization of infants in the USA. During the following years, a number of studies documented the impact of this immunization program on rates of invasive pneumococcal disease, pneumonia and otitis media. This article aims to summarize current evidence on the population-based impact of this infant immunization program in the USA.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources